Monte Rosa Therapeutics (Nasdaq: GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE